logo
Cyclosporin Monitoring in Australasia: 2002 Update of Consensus Guidelines
Prediction of Unbound Propofol Concentrations in a Diabetic Population
Effect of Analytical Inaccuracy on Dose Adjustment for Vancomycin, Amikacin, and Tobramycin Using the Abbottbase® Pharmacokinetic Systems
Dosage of Ribavirin in Patients With Hepatitis C Should Be Based on Renal Function: A Population Pharmacokinetic Analysis
Population Pharmacokinetics of Etoposide: Application to Therapeutic Drug Monitoring
Influence of the Urine Flow Rate on Some Caffeine Metabolite Ratios Used to Assess CYP1A2 Activity
A Wide Interindividual Variability of Urinary 6β-Hydroxycortisol to Free Cortisol in 487 Healthy Japanese Subjects in Near Basal Condition
Monitoring Adverse Drug Reactions to Sulfonamide Antibiotics in Human Immunodeficiency Virus–Infected Individuals
Evidence of Polymorphic CYP2C19 Involvement in the Human Metabolism of N-Desmethylclobazam
Population Pharmacokinetics of Digoxin in Pediatric Patients
Monitoring Urinary Excretion of Cannabinoids by Fluorescence-Polarization Immunoassay: A Cannabinoid-to-Creatinine Ratio Study
Measurement of Whole Blood Sirolimus by an HPLC Assay Using Solid-Phase Extraction and UV Detection
Simultaneous and Rapid Analysis of Cyclosporin A and Creatinine in Finger Prick Blood Samples Using Liquid Chromatography Tandem Mass Spectrometry and Its Application in C2 Monitoring
Solid-Phase Microextraction of Human Plasma Samples for Determination of Sufentanil by Gas Chromatography–Mass Spectrometry
Spurious Results in Therapeutic Drug Monitoring Research
Relationship Between Cyclosporine Concentrations Obtained Using the Roche Cobas Integra and Abbott TDx Monoclonal Immunoassays in Pre-dose and Two Hour Post-dose Blood Samples from Kidney Transplant Recipients
Therapeutic Drug Monitoring on COBAS INTEGRA 400: Reply to Hermida, et al. in Therapeutic Drug Monitoring 2001;23:725–727(1)